Share Email Print

Proceedings Paper

In situ photoimmunotherapy for advanced cutaneous melanoma
Author(s): Mark F. Naylor; Robert E. Nordquist; T. Kent Teague; David A. Adelson; Lisa A. Perry; Wei R. Chen
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.

Paper Details

Date Published: 28 February 2008
PDF: 5 pages
Proc. SPIE 6857, Biophotonics and Immune Responses III, 685702 (28 February 2008); doi: 10.1117/12.764970
Show Author Affiliations
Mark F. Naylor, Univ. of Oklahoma College of Medicine (United States)
Robert E. Nordquist, Advanced Cancer Therapies L.L.C. (United States)
T. Kent Teague, Univ. of Oklahoma Colleges of Medicine and Pharmacy (United States)
Oklahoma State Univ. Ctr. for Health Sciences (United States)
David A. Adelson, Univ. of Oklahoma College of Medicine (United States)
Lisa A. Perry, Univ. of Oklahoma College of Medicine (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)

Published in SPIE Proceedings Vol. 6857:
Biophotonics and Immune Responses III
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?